- Home
- EQ vs VNCE Comparison
EQ vs VNCE Comparison
Compare EQ & VNCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- VNCE
- Stock Information
- Founded
- EQ 2017
- VNCE 2002
- Country
- EQ United States
- VNCE United States
- Employees
- EQ N/A
- VNCE N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- VNCE Clothing/Shoe/Accessory Stores
- Sector
- EQ Health Care
- VNCE Consumer Discretionary
- Exchange
- EQ Nasdaq
- VNCE Nasdaq
- Market Cap
- EQ 24.8M
- VNCE 25.2M
- IPO Year
- EQ 2018
- VNCE 2013
- Fundamental
- Price
- EQ $0.74
- VNCE $1.71
- Analyst Decision
- EQ Buy
- VNCE Strong Buy
- Analyst Count
- EQ 2
- VNCE 2
- Target Price
- EQ $5.00
- VNCE $3.00
- AVG Volume (30 Days)
- EQ 304.3K
- VNCE 10.5K
- Earning Date
- EQ 11-13-2024
- VNCE 12-04-2024
- Dividend Yield
- EQ N/A
- VNCE N/A
- EPS Growth
- EQ N/A
- VNCE N/A
- EPS
- EQ N/A
- VNCE 0.10
- Revenue
- EQ $45,914,000.00
- VNCE $292,727,000.00
- Revenue This Year
- EQ N/A
- VNCE $0.48
- Revenue Next Year
- EQ N/A
- VNCE $5.47
- P/E Ratio
- EQ N/A
- VNCE $17.89
- Revenue Growth
- EQ 7.70
- VNCE N/A
- 52 Week Low
- EQ $0.48
- VNCE $1.15
- 52 Week High
- EQ $3.25
- VNCE $4.73
- Technical
- Relative Strength Index (RSI)
- EQ 40.86
- VNCE 40.99
- Support Level
- EQ $0.66
- VNCE $1.69
- Resistance Level
- EQ $0.77
- VNCE $1.80
- Average True Range (ATR)
- EQ 0.08
- VNCE 0.08
- MACD
- EQ -0.01
- VNCE -0.01
- Stochastic Oscillator
- EQ 26.09
- VNCE 6.25
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
About VNCE Vince Holding Corp.
Vince Holding Corp is a fashion brand that is engaged in wholesale and retail delivery of luxury essentials like women's and men's apparel, women's and men's footwear, and handbags. Its offers women's collections of luxurious cashmere sweaters and silk blouses, leather and suede leggings and jackets, dresses, denim, pants, tanks and t-shirts, and a growing assortment of outerwear. It focuses on developing an elevated collection of Vince apparel and accessories to serve the luxurious need of the customer. The company manages its business in three segments namely Vince Wholesale, Vince Direct-to-consumer, and Rebecca Taylor and Parker segment. It operates its e-commerce business through its website. Majority of its revenue generated from Vince Wholesale segment.